Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xilio Therapeutics (XLO) Operating Expenses (2024 - 2025)

Xilio Therapeutics' Operating Expenses history spans 2 years, with the latest figure at $21.0 million for Q3 2025.

  • For Q3 2025, Operating Expenses rose 23.32% year-over-year to $21.0 million; the TTM value through Sep 2025 reached $75.6 million, changed N/A, while the annual FY2024 figure was $66.9 million, 15.43% down from the prior year.
  • Operating Expenses for Q3 2025 was $21.0 million at Xilio Therapeutics, down from $22.4 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $22.4 million in Q2 2025 and bottomed at $15.4 million in Q4 2024.